The International Myeloma Foundation is pleased to report another important step toward approval of Revlimid for multiple myeloma, this time in Europe.
Celgene reports that the European Medicines Agency, the EMEA, has accepted for review Celgene’s application to make Revlimid available to patients with relapsed or refractory multiple myeloma. This means Revlimid is under review for myeloma by the corresponding government agencies in both the US and in Europe.
At IMF European headquarters, as at our global headquarters in the United States, we are available to support expeditious regulatory review of Revlimid. We believe Revlimid will be a much needed addition to the arsenal of drugs available to treat myeloma. Data from the Xth International Myeloma Workshop in Sydney shows that Revlimid can help improve overall survival and delay time to disease progression in previously treated patients.
Based on the EMEA action, Revlimid could be approved for use in myeloma in Europe at the start of next year. It could get FDA approval for myeloma in the U.S. later this spring. Read Celgene's press release in English, German, Italian, French, Japanese and Spanish by clicking on the icons to your right.